Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial
Journal of Investigational Allergology and Clinical Immunology · 2025
DOI: 10.18176/jiaci.1003 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Investigational Allergology and Clinical Immunology, 2025. Verfasst von B Majorek-Olechowska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o., Tarnów, Poland. Hauptthemen laut MEDLINE: Benzimidazoles, Urticaria, Piperidines, Conjunctivitis, Allergic. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Bilastine is a second-generation antihistamine for the symptomatic treatment of allergic rhinoconjunctivitis (ARC) and urticaria in adults, adolescents, and children. The pharmacokinetics and safety of oral bilastine 10 mg/d in children aged 2 to 5 years were evaluated.
Methods
This was a multicenter, open-label clinical trial in children aged 2 to 5 years with seasonal or perennial ARC or urticaria treated once daily with bilastine 10 mg orodispersible tablets. The safety evaluation included treatment-emergent adverse events (TEAEs), vital signs, and physical examination. Pharmacokinetic data were pooled with data from a prior pediatric study, and pharmacokinetic modeling was performed to assess consistency.
Results
A total of 37 children with ARC (81.1%), urticaria (8.1%), or both (10.8%) were included in the study, with a mean (SD) age of 3.7 (1.2) years. The highest plasma concentrations of bilastine were observed 1 hour after administration (634.91 ng/mL). Eight patients (21.6%) experienced 1 TEAE each, none of which was severe. Body weight and age were not covariates of variation in either systemic clearance or the volume of distribution in children aged 2 to 5 years and did not affect the pharmacokinetic parameters of bilastine.
Conclusions
The pharmacokinetics of bilastine was linear and consistent with data from a previous trial, suggesting that a 10-mg dose may be used in children (2 to
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alergo-Med Specjalistyczna Przychodnia Lekarska Sp. z o.o., Tarnów, Poland.
- Center of Allergy Diagnosis and Treatment, Vilnius, Lithuania.
- Ambulancia Klinickej Imunológie a Alergiológie - Allergy Ambulance, Rimavská Sobota, Slovakia.
- Department of Research, Development, and Innovation, FAES FARMA, Leioa, Spain.
Zitieren
APA
Majorek-Olechowska, B., Slomskis, T., Zollerová, L., Martín, I., Sánchez, C., Gilaberte, I., Arranz, P., & BILA-4021/PED Research Group (2025). Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial. Journal of Investigational Allergology and Clinical Immunology. https://doi.org/10.18176/jiaci.1003
Vancouver
Majorek-Olechowska B, Slomskis T, Zollerová L, Martín I, Sánchez C, Gilaberte I, et al. Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial. Journal of Investigational Allergology and Clinical Immunology. 2025. doi:10.18176/jiaci.1003
BibTeX
@article{MajorekOlechowska2025,
author = {Majorek-Olechowska, B and Slomskis, T and Zollerová, L and Martín, I and Sánchez, C and Gilaberte, I and Arranz, P and BILA-4021/PED Research Group, BILA-4021/PED Research Group},
title = {Pharmacokinetics and Safety of Bilastine 10 mg/d in Children Aged 2 to 5 Years With Allergic Rhinoconjunctivitis or Urticaria: A Phase 3 Clinical Trial},
journal = {Journal of Investigational Allergology and Clinical Immunology},
year = {2025},
doi = {10.18176/jiaci.1003}
}
EUVIMED